IN2014CN04374A - - Google Patents

Info

Publication number
IN2014CN04374A
IN2014CN04374A IN4374CHN2014A IN2014CN04374A IN 2014CN04374 A IN2014CN04374 A IN 2014CN04374A IN 4374CHN2014 A IN4374CHN2014 A IN 4374CHN2014A IN 2014CN04374 A IN2014CN04374 A IN 2014CN04374A
Authority
IN
India
Prior art keywords
fragments
antibodies
ligand
bind
inhibit
Prior art date
Application number
Inventor
Winfried Elis
Seth Ettenberg
Andrew Paul Garner
Nicole Haubst
Heather Huet
Christian Carsten Silvester Kunz
Sprague Elizabeth Anne Reisinger
Qing Sheng
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IN2014CN04374A publication Critical patent/IN2014CN04374A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to antibodies or fragments thereof that bind to a non linear epitope within domain 3 of the HER3 receptor and inhibit both ligand dependent and ligand independent signal transduction. The invention also relates antibodies or fragments thereof that bind to amino acid residues within domains 3 4 of HER3 and inhibit both ligand dependent and ligand independent signal transduction; and compositions and methods of use of such antibodies or fragments thereof.
IN4374CHN2014 2011-12-05 2012-12-04 IN2014CN04374A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161566912P 2011-12-05 2011-12-05
PCT/IB2012/056956 WO2013084151A2 (en) 2011-12-05 2012-12-04 Antibodies for epidermal growth factor receptor 3 (her3) directed to domain iii and domain iv of her3

Publications (1)

Publication Number Publication Date
IN2014CN04374A true IN2014CN04374A (en) 2015-09-04

Family

ID=47561692

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4374CHN2014 IN2014CN04374A (en) 2011-12-05 2012-12-04

Country Status (16)

Country Link
EP (1) EP2788381A2 (en)
JP (1) JP2015500830A (en)
KR (1) KR20140099315A (en)
CN (1) CN104093742A (en)
AR (1) AR089085A1 (en)
AU (1) AU2012349739A1 (en)
BR (1) BR112014013495A2 (en)
CA (1) CA2857939A1 (en)
EA (1) EA201491120A1 (en)
IL (1) IL232950A0 (en)
IN (1) IN2014CN04374A (en)
MX (1) MX2014006731A (en)
SG (1) SG11201402784WA (en)
TW (1) TW201331225A (en)
UY (1) UY34488A (en)
WO (1) WO2013084151A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301147A (en) * 2014-02-28 2023-05-01 Merus Nv Antibody that binds erbb-2 and erbb-3
ES2816624T3 (en) 2014-02-28 2021-04-05 Merus Nv Antibodies that bind EGFR and ERBB3
CN107257691B (en) 2014-07-16 2021-09-21 达娜-法勃肿瘤研究所公司 HER3 inhibition in low-grade serous ovarian cancer
CN104530237B (en) * 2014-12-31 2017-09-05 百泰生物药业有限公司 Anti- Her1 therapeutic antibodies
EP3912998A3 (en) 2015-10-23 2022-02-23 Merus N.V. Binding molecules that inhibit cancer growth
JP6729926B2 (en) * 2016-05-12 2020-07-29 国立大学法人神戸大学 ErbB3 activation signal transduction inhibitor and method for screening the same
JP7203426B2 (en) * 2016-09-15 2023-01-13 ウニヴェルズィテート シュトゥットガルト Antigen binding protein for HER3
KR101923641B1 (en) * 2016-11-25 2018-11-29 재단법인 목암생명과학연구소 Anti-HER3 antibody and composition for preventing or treating cancer comprising the same
JP2020511993A (en) 2017-03-31 2020-04-23 メルス ナムローゼ フェンノートシャップ ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells carrying the NRG1 fusion gene
WO2019031965A1 (en) 2017-08-09 2019-02-14 Merus N.V. Antibodies that bind egfr and cmet

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR056857A1 (en) * 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
US8362215B2 (en) * 2009-04-29 2013-01-29 Trellis Bioscience, Llc Antibodies immunoreactive with heregulin-coupled HER3
ES2655737T3 (en) * 2009-11-13 2018-02-21 Daiichi Sankyo Europe Gmbh Materials and methods to treat or prevent diseases associated with HER-3
ES2566602T3 (en) * 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
TW201302793A (en) * 2010-09-03 2013-01-16 Glaxo Group Ltd Novel antigen binding proteins
ES2657862T3 (en) * 2011-05-13 2018-03-07 Gamamabs Pharma Antibodies against HER3
EP2736928B1 (en) * 2011-07-28 2019-01-09 i2 Pharmaceuticals, Inc. Sur-binding proteins against erbb3

Also Published As

Publication number Publication date
BR112014013495A8 (en) 2017-06-13
BR112014013495A2 (en) 2017-06-13
IL232950A0 (en) 2014-07-31
MX2014006731A (en) 2015-06-04
AU2012349739A1 (en) 2014-06-26
CN104093742A (en) 2014-10-08
UY34488A (en) 2013-07-31
SG11201402784WA (en) 2014-06-27
AR089085A1 (en) 2014-07-30
EA201491120A1 (en) 2015-07-30
EP2788381A2 (en) 2014-10-15
JP2015500830A (en) 2015-01-08
WO2013084151A3 (en) 2014-01-03
CA2857939A1 (en) 2013-06-13
TW201331225A (en) 2013-08-01
WO2013084151A2 (en) 2013-06-13
KR20140099315A (en) 2014-08-11

Similar Documents

Publication Publication Date Title
IN2014CN04374A (en)
IN2014CN04373A (en)
MX350957B (en) Binding molecules specific for her3 and uses thereof.
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
GEP201706605B (en) Antibodies for epidermal growth factor receptor 3 (her3)
EA201200195A1 (en) ANTIBODIES AGAINST EKTODOMENA ErbB3 AND THEIR APPLICATION
UA117901C2 (en) Antibody variants and uses thereof
MX353706B (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use.
JO3118B1 (en) Compositions and methods for antibodies targeting complement protein c5
UA106070C2 (en) Antibody that specifically binds to egfr and her3
MX362039B (en) Anti-il-23 antibodies.
MX356279B (en) Methods of treating psoriasis using il-17 antagonists.
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MX360403B (en) Amyloid-beta binding proteins.
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
JO3437B1 (en) Improved anti human Fraktalkine antibodies and uses thereof
WO2009002380A3 (en) Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies
MX2013002960A (en) Antibody compositions and methods of use.
WO2015048008A3 (en) Binding molecules specific for her3 and uses thereof
WO2010118203A3 (en) Endosialin binding molecules
MX2015004892A (en) Methods and compositions relating to anti-il-21 receptor antibodies.
TN2011000041A1 (en) Compositions and methods for antibodies targeting complement protein c5
TN2013000040A1 (en) Antibodies for epidermal growth factor receptor 3 (her3)
TR201909300T4 (en) Methods and compositions for preparing aerosols.
SG10201909377XA (en) Antibodies that bind human cd27 and uses thereof